SEC Form 4 · accession 0001209191-15-039904
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis Karl Huang
Officer — SVP & Chief TechOps Officer
Period of report
May 5, 2015
Accepted (ET)
May 7, 2015 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 5, 2015 | A | 7,500 | — | A | 7,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $62.63 | May 5, 2015 | A | 60,000 | A | — | May 4, 2025 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the Company's 2014 Incentive Plan that vests with respect to 1/4th of the underlying shares on May 4, 2016 and then with respect to 1/4th of the underlying shares annually thereafter.
- F2Not applicable.
- F3The option shall vest with respect to 1/4th of the underlying shares on May 4, 2016 and then with respect to 1/48th of the underlying shares monthly thereafter.